# Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

> **NCT01973543** · PHASE1 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 15 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **BIOLOGICAL:** VY-AADC01

## Key facts

- **NCT ID:** NCT01973543
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2020-01-24
- **Final completion:** 2020-01-24
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01973543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01973543, "Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01973543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*